Novel antibacterial target: an essential glycoprotease

新型抗菌靶点:必需的糖蛋白酶

基本信息

  • 批准号:
    7230236
  • 负责人:
  • 金额:
    $ 18.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-04-01 至 2009-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The emergence of multi-drug resistant bacterial pathogens, especially methicillin-resistant and vancomycin intermediate-resistant Staphylococcus aureus is generating an enormous public health concern. Many of these pathogens are capable of causing severe and even fatal infections with limited options for therapy. The slowdown in the discovery of novel classes of antibiotics in past several decades and the recent downturn in antibacterial discovery and development in the pharmaceutical industry is making us more vulnerable to emerging resistance. Therefore, there is an urgent need for new, alternative agents for treating multi-drug-resistant pathogens. The recent availability of the complete genome sequences for pathogens enables us to undertake a systematic and comprehensive evaluation of the requirement for each and every gene/operon for both bacterial growth and infection. The gene products essential for bacterial growth in vitro and survival during infection constitute an initial set of validated protein targets that can be optimized and automated screens. Our long-term goal is to identify novel targets for delivering efficacious preventive and/or therapeutic agents against S. aureus infections. The specific hypothesis is that a putative glycoprotease (Gcp) is a novel antibacterial target involved in the pathway required for bacterial survival. However, the biological function of Gcp and its importance for growth and survival remains unclear. Elucidation of the precise function of Gcp will lead to the basis for the development of an in vitro assay, which is indispensable for the drug discovery. Therefore, the objective of this proposal is to determine the biological function of Gcp, identify pathway that Gcp is involved in, and to develop a potential assay. We will pursue the following three specific aims to test our central hypothesis: First, we will characterize the essential putative glycoprotease of S. aureus. Second, we will employ microarray technology to identify staphylococcal genes, transcriptions of which are affected by conditional inactivation of putative glycoprotease function. Third, we will utilize proteomic approaches to identify proteins that are affected by down-regulation of gcp expression and compare this data with microarray data.
描述(由申请人提供):多重耐药细菌病原体的出现,特别是耐甲氧西林和万古霉素中度耐药金黄色葡萄球菌,正在引起巨大的公共卫生问题。这些病原体中的许多能够引起严重甚至致命的感染,治疗选择有限。在过去的几十年里,新型抗生素的发现速度放缓,以及制药行业抗菌药物发现和开发的近期低迷,使我们更容易受到新出现的耐药性的影响。因此,迫切需要用于治疗多重耐药病原体的新的替代剂。病原体的完整基因组序列的最近可用性使我们能够对细菌生长和感染的每个基因/操纵子的需求进行系统和全面的评估。细菌在体外生长和感染期间存活所必需的基因产物构成了一组初始的经验证的蛋白质靶点,可以进行优化和自动筛选。我们的长期目标是确定新的目标,提供有效的预防和/或治疗剂对S。金黄色葡萄球菌感染具体的假设是,一个假定的糖蛋白酶(Gcp)是一种新的抗菌靶标参与细菌生存所需的途径。然而,Gcp的生物学功能及其对生长和存活的重要性仍不清楚。阐明Gcp的确切功能将为开发体外测定奠定基础,这对于药物发现是不可或缺的。因此,本提案的目的是确定Gcp的生物学功能,确定Gcp参与的途径,并开发潜在的检测方法。我们将追求以下三个具体目标来检验我们的中心假设:首先,我们将描述S.金黄色。其次,我们将采用微阵列技术来确定葡萄球菌的基因,其中transenergies的影响,假定的糖蛋白酶功能的条件失活。第三,我们将利用蛋白质组学的方法来鉴定受gcp表达下调影响的蛋白质,并将这些数据与微阵列数据进行比较。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yinduo Ji其他文献

Yinduo Ji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yinduo Ji', 18)}}的其他基金

Biomarker Screening of Essential Putative Glycoprotease Inhibitor
必需的假定糖蛋白酶抑制剂的生物标志物筛选
  • 批准号:
    8071522
  • 财政年份:
    2010
  • 资助金额:
    $ 18.15万
  • 项目类别:
Biomarker Screening of Essential Putative Glycoprotease Inhibitor
必需的假定糖蛋白酶抑制剂的生物标志物筛选
  • 批准号:
    7779870
  • 财政年份:
    2010
  • 资助金额:
    $ 18.15万
  • 项目类别:
Biomarker Screening of Essential Putative Glycoprotease Inhibitor
必需的假定糖蛋白酶抑制剂的生物标志物筛选
  • 批准号:
    8259532
  • 财政年份:
    2010
  • 资助金额:
    $ 18.15万
  • 项目类别:
Novel antibacterial target: an essential glycoprotease
新型抗菌靶点:必需的糖蛋白酶
  • 批准号:
    7097649
  • 财政年份:
    2006
  • 资助金额:
    $ 18.15万
  • 项目类别:
A Novel Essential Regulator of Staphylococcus aureus
金黄色葡萄球菌的新型必需调节剂
  • 批准号:
    7069489
  • 财政年份:
    2005
  • 资助金额:
    $ 18.15万
  • 项目类别:
A Novel Essential Regulator of Staphylococcus aureus
金黄色葡萄球菌的新型必需调节剂
  • 批准号:
    7196421
  • 财政年份:
    2005
  • 资助金额:
    $ 18.15万
  • 项目类别:
A Novel Essential Regulator of Staphylococcus aureus
金黄色葡萄球菌的新型必需调节剂
  • 批准号:
    6968033
  • 财政年份:
    2005
  • 资助金额:
    $ 18.15万
  • 项目类别:
A Novel Essential Regulator of Staphylococcus aureus
金黄色葡萄球菌的新型必需调节剂
  • 批准号:
    7369903
  • 财政年份:
    2005
  • 资助金额:
    $ 18.15万
  • 项目类别:

相似海外基金

New technologies for targeted delivery of anti-bacterial agents
抗菌药物靶向递送新技术
  • 批准号:
    1654774
  • 财政年份:
    2015
  • 资助金额:
    $ 18.15万
  • 项目类别:
    Studentship
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
  • 批准号:
    8416313
  • 财政年份:
    2012
  • 资助金额:
    $ 18.15万
  • 项目类别:
Targeting bacterial phosphatases for novel anti-bacterial agents.
针对细菌磷酸酶的新型抗菌剂。
  • 批准号:
    8298885
  • 财政年份:
    2012
  • 资助金额:
    $ 18.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了